Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI) a pragmatic, open-label, non-inferiority, randomised controlled trial

Authors :: Linschoten, Reinier C.A. van
Jansen, F.M.
Pauwels, Renske W.M.
Smits, Lisa J.T.
Atsma, F.
Kievit, W.
Jong, D.J. de
Jansen, Jeroen
Janneke van der Woude, C.
Hoentjen, F.
Linschoten, Reinier C.A. van
Jansen, F.M.
Pauwels, Renske W.M.
Smits, Lisa J.T.
Atsma, F.
Kievit, W.
Jong, D.J. de
Jansen, Jeroen
Janneke van der Woude, C.
Hoentjen, F.
Source :: Lancet Gastroenterology & Hepatology; 343; 355; 2468-1253; 4; 8; ~Lancet Gastroenterology & Hepatology~343~355~~~2468-1253~4~8~~
Publication Year :: 2023
Abstract: Item does not contain fulltext

Database :: OAIster
Journal :: Lancet Gastroenterology & Hepatology; 343; 355; 2468-1253; 4; 8; ~Lancet Gastroenterology & Hepatology~343~355~~~2468-1253~4~8~~
Publication Type :: Electronic Resource
Accession number :: edsoai.on1382781825
Document Type :: Electronic Resource

Tools